The European cell sheet-based gene approach market is experiencing significant expansion. This sector is driven by an increasing need for innovative therapeutic solutions to address a broad range of genetic conditions. Effective clinical trials and regulatory sanctions are fueling market momentum. A key factor contributing to this phenomenon is the